157 related articles for article (PubMed ID: 32814048)
21. Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.
Usardi A; Pooler AM; Seereeram A; Reynolds CH; Derkinderen P; Anderton B; Hanger DP; Noble W; Williamson R
FEBS J; 2011 Aug; 278(16):2927-37. PubMed ID: 21692989
[TBL] [Abstract][Full Text] [Related]
22. Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25-35): involvement of lipid rafts.
Hernandez P; Lee G; Sjoberg M; Maccioni RB
J Alzheimers Dis; 2009; 16(1):149-56. PubMed ID: 19158430
[TBL] [Abstract][Full Text] [Related]
23. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
[TBL] [Abstract][Full Text] [Related]
24. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
25. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.
Ittner LM; Ke YD; Delerue F; Bi M; Gladbach A; van Eersel J; Wölfing H; Chieng BC; Christie MJ; Napier IA; Eckert A; Staufenbiel M; Hardeman E; Götz J
Cell; 2010 Aug; 142(3):387-97. PubMed ID: 20655099
[TBL] [Abstract][Full Text] [Related]
26. Fyn, a potential target for Alzheimer's disease.
Yang K; Belrose J; Trepanier CH; Lei G; Jackson MF; MacDonald JF
J Alzheimers Dis; 2011; 27(2):243-52. PubMed ID: 21799250
[TBL] [Abstract][Full Text] [Related]
27. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
28. Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease.
Zahratka JA; Shao Y; Shaw M; Todd K; Formica SV; Khrestian M; Montine T; Leverenz JB; Bekris LM
Neurobiol Aging; 2017 Mar; 51():43-53. PubMed ID: 28033507
[TBL] [Abstract][Full Text] [Related]
29. A local insult of okadaic acid in wild-type mice induces tau phosphorylation and protein aggregation in anatomically distinct brain regions.
Baker S; Götz J
Acta Neuropathol Commun; 2016 Mar; 4():32. PubMed ID: 27037086
[TBL] [Abstract][Full Text] [Related]
30. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
Demuro S; Sauvey C; Tripathi SK; Di Martino RMC; Shi D; Ortega JA; Russo D; Balboni B; Giabbai B; Storici P; Girotto S; Abagyan R; Cavalli A
Eur J Med Chem; 2022 Feb; 229():114054. PubMed ID: 34959172
[TBL] [Abstract][Full Text] [Related]
31. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
32. AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo.
Domise M; Didier S; Marinangeli C; Zhao H; Chandakkar P; Buée L; Viollet B; Davies P; Marambaud P; Vingtdeux V
Sci Rep; 2016 May; 6():26758. PubMed ID: 27230293
[TBL] [Abstract][Full Text] [Related]
33. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
34. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
35. Homocysteine Increases Tau Phosphorylation, Truncation and Oligomerization.
Shirafuji N; Hamano T; Yen SH; Kanaan NM; Yoshida H; Hayashi K; Ikawa M; Yamamura O; Kuriyama M; Nakamoto Y
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562600
[TBL] [Abstract][Full Text] [Related]
36. The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy.
Soler H; Dorca-Arévalo J; González M; Rubio SE; Ávila J; Soriano E; Pascual M
Neurobiol Aging; 2017 Jan; 49():40-51. PubMed ID: 27743524
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation of tau by fyn: implications for Alzheimer's disease.
Lee G; Thangavel R; Sharma VM; Litersky JM; Bhaskar K; Fang SM; Do LH; Andreadis A; Van Hoesen G; Ksiezak-Reding H
J Neurosci; 2004 Mar; 24(9):2304-12. PubMed ID: 14999081
[TBL] [Abstract][Full Text] [Related]
38. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
39. Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β.
Vossel KA; Xu JC; Fomenko V; Miyamoto T; Suberbielle E; Knox JA; Ho K; Kim DH; Yu GQ; Mucke L
J Cell Biol; 2015 May; 209(3):419-33. PubMed ID: 25963821
[TBL] [Abstract][Full Text] [Related]
40. Pathological Changes of Tau Related to Alzheimer's Disease.
Chu D; Liu F
ACS Chem Neurosci; 2019 Feb; 10(2):931-944. PubMed ID: 30346708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
